Whole Genome Sequencing (WGS) is a process of sequencing the entire genome of an individual with an unknown genomic sequence. By utilizing high-throughput sequencing technologies, WGS can rapidly and cost-effectively determine the entire genome sequence of an organism. In this context, Erin Connolly-Strong will delve into the Clinics WGS application based on MGI's DNBSQ-T7, highlighting its potential and practical applications in cancer genomics and rare disease diagnosis.

Cancer is a major global health issue, responsible for about one-sixth of all deaths, surpassing the combined toll of AIDS, tuberculosis, and malaria. It ranks as the top cause of mortality in numerous countries. Technological progress, especially in genomics, has enhanced our grasp of cancer's triggers and fostered precision oncology. In this context, Dr. Marie-Laure Yaspo at ALACRIS Theranostics aims to bridge the care divide with scientifically-backed cancer management methods throughout the patient journey, from prevention to therapy, leveraging MGI's advanced life science tools.

Launched in 2019, the Million Microbiome of Humans Project, a collaboration among scientists from 21 institutions across 10+ countries, aims to analyze 1 million microbial samples from various human organs within 3-5 years, using metagenomic sequencing to create the largest global human microbiome database.

Comprehensive genomic profiling is essential for precision oncology. The speakers evaluated cancer gene panels on MGI's G400 and G99 DNBSEQ systems. Agilent's assay offers tumor profiling on G400; GenePLUS has a 1021-gene panel; NGeneBio targets 18-343 genes for various cancers. These systems achieve >90% Q30, >50X coverage, detecting variants down to 1% allele frequency. MGI's systems offer speed, scalability, and cost-effectiveness, supporting both large and targeted panels for cancer research and diagnostics, advancing genomic medicine.

Unravel the mysteries of B and T cell expansions with cutting-edge TCR and BCR sequencing. Join us as we explore the latest advancements in RNA profiling, V(D)J analysis, and spatial biology technologies for comprehensive immune profiling.

Alacris Theranostics' Comprehensive Molecular Tumor Analysis (CMTA) uses whole exome and transcriptome sequencing with MGI DNBSEQ technology. It's beneficial for guiding targeted therapies in complex or unknown tumors, enhancing personalized cancer treatment plans.

Stereo-seq, based on DNA Nanoball (DNB) technology, offers spatially resolved, single-cell gene expression profiling in tissue slices. It supports advanced analysis in the Human Protein Atlas program, enhancing coverage and resolution. The webinar highlights its use in research, along with STOmics' new bioinformatic tools and automation system.

Learn how Next-Generation Sequencing is reshaping agriculture, improving plant and animal breeding. Through case studies, we illustrate how NGS enables efficient selection, promoting faster, cost-effective breeding strategies.

Discover how we revolutionized high-throughput DNA sequencing into a crucial diagnostic tool at NoorDx, Saudi Arabia using MGI platforms, underscoring the significance of genome analysis in healthcare decisions.

Sequencing larger regions of the genome offers more information to clinicians looking for potential disease causing variants to help diagnose their patients. This webinar demonstrates the full workflow from sample to report generation covering, exome sequencing with MGI’s DNBSeq-T7, NGS data analysis and interpretation with VarSome Clinical, and Gencell's approach and experience using both.